论文部分内容阅读
OBJECTIVE:To investigate the efficacy and safety of Sodium tanshinone Ⅱ A sulfonate(STS)plus the conventional treatment on acute myocardial infarc-tion(AMI)patients.METHODS:We searched several electrical databas-es and hand searched several Chinese medicaljour-nals up to January 2019.Randomized controlled tri-als(RCTs)comparing STS plus conventional treat-ment with conventional treatment were retrieved.Study screening,data extraction,quality assess-ment,and data analysis were conducted in accor-dance with the Cochrane standards.RESULTS:Sixteen trials involving 1383 people were included.The Meta-analysis showed STS combined with conventional treatment was a better treat-ment option than conventional treatment alone in reducing the risk of mortality,heart failure,arrhyth-mia and shock.In addition,STS was associated with improvement in left ventricular ejection fraction(LVEF)and left ventricular end diastolic dimension(LVEDD).No significant difference of STS was found on recurrent angina and recurrent AMI.However,the safety of STS remained uncertain for limited data.CONCLUSION:Compared with conventional treat-ment alone,STS combined with conventional treat-ment may provide more benefits for patients with AMI.Due to the fact that the overall quality of all in-cluded trials is generally low,further large-scale high quality trials are warranted.